Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)

NCT00056173 is registered in ClinicalTrials.gov with Aptose Biosciences Inc. as lead sponsor.

NCT NCT00056173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00056173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)
Lead sponsor
Aptose Biosciences Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2002
Completion date
Not reported
Enrollment
43 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell, metastases, neoplasm